Trial · NCT00244621
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
NCT00244621, Phase 3, Completed, AstraZeneca; results first posted 2009-09-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age. Trials, record NCT00244621. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00244621
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
- NCT number
- NCT00244621
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 95 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Hypertension
- Interventions
- candesartan cilexetil (Atacand), candesartan cilexetil (Atacand), candesartan cilexetil (Atacand)
- First posted
- 2005-10-27
- Last updated
- 2011-08-31
- Results first posted
- 2009-09-15
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP) | From randomisation to end of double-blind treatment (4 weeks) | |
| Secondary | Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP) | From randomisation to end of double-blind treatment (4 weeks) | |
| Secondary | Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | From randomisation to day 28 | |
| Secondary | Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | From randomisation to day 28 |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP) | From randomisation to end of double-blind treatment (4 weeks) | mm Hg | MEAN | |
| SECONDARY | Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP) | From randomisation to end of double-blind treatment (4 weeks) | mm Hg | MEAN | |
| SECONDARY | Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | From randomisation to day 28 | Percent change | MEDIAN | |
| SECONDARY | Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | From randomisation to day 28 | Percent change | MEDIAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP) | Atacand .05 mg | -6.0 | Standard Deviation 9.4 | mm Hg | |
| Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP) | Atacand .20 mg | -8.9 | Standard Deviation 9.2 | mm Hg | |
| Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP) | Atacand .40 mg | -12.0 | Standard Deviation 8.3 | mm Hg | |
| Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP) | Atacand .05 mg | -5.2 | Standard Deviation 6.7 | mm Hg | |
| Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP) | Atacand .20 mg | -7.9 | Standard Deviation 12.9 | mm Hg | |
| Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP) | Atacand .40 mg | -11.1 | Standard Deviation 9.2 | mm Hg | |
| Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | Atacand .05 mg | -11.1 | Inter-Quartile Range -42.5 to 33.3 | Percent change | |
| Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | Atacand .20 mg | -40.6 | Inter-Quartile Range -68.1 to 25.0 | Percent change | |
| Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | Atacand .40 mg | -50.0 | Inter-Quartile Range -68.9 to 15.8 | Percent change | |
| Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28 | Atacand .05 mg | 0.0 | Inter-Quartile Range -25.0 to 50.0 | Percent change |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Treatment Period | STARTED | Atacand .05 mg | 29 | |
| Double-blind Treatment Period | STARTED | Atacand .20 mg | 32 | |
| Double-blind Treatment Period | STARTED | Atacand .40 mg | 32 | |
| Double-blind Treatment Period | COMPLETED | Atacand .05 mg | 27 | |
| Double-blind Treatment Period | COMPLETED | Atacand .20 mg | 29 | |
| Double-blind Treatment Period | COMPLETED | Atacand .40 mg | 30 | |
| Double-blind Treatment Period | NOT COMPLETED | Atacand .05 mg | 2 | |
| Double-blind Treatment Period | NOT COMPLETED | Atacand .20 mg | 3 | |
| Double-blind Treatment Period | NOT COMPLETED | Atacand .40 mg | 2 | |
| Open-label Treatment Period | STARTED | Atacand .05 mg | 26 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Lymphadenitis | Blood and lymphatic system disorders | Atacand .05 mg | 0 | 29 | |
| serious | Lymphadenitis | Blood and lymphatic system disorders | Atacand .20 mg | 1 | 32 | |
| serious | Lymphadenitis | Blood and lymphatic system disorders | Atacand .40 mg | 0 | 32 | |
| serious | Catheter Site Haematoma | Blood and lymphatic system disorders | Atacand .05 mg | 1 | 29 | |
| serious | Catheter Site Haematoma | Blood and lymphatic system disorders | Atacand .20 mg | 0 | 32 | |
| serious | Catheter Site Haematoma | Blood and lymphatic system disorders | Atacand .40 mg | 0 | 32 | |
| serious | Catheter Site Necrosis | Blood and lymphatic system disorders | Atacand .05 mg | 1 | 29 | |
| serious | Catheter Site Necrosis | Blood and lymphatic system disorders | Atacand .20 mg | 0 | 32 | |
| serious | Catheter Site Necrosis | Blood and lymphatic system disorders | Atacand .40 mg | 0 | 32 | |
| serious | Pyrexia | Blood and lymphatic system disorders | Atacand .05 mg | 0 | 29 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atacand .05 mg | ||
| Total, all-cause mortality | Atacand .20 mg | ||
| Total, all-cause mortality | Atacand .40 mg | ||
| Total, other adverse events | Atacand .05 mg | 0 | 29 |
| Total, other adverse events | Atacand .20 mg | 0 | 32 |
| Total, other adverse events | Atacand .40 mg | 0 | 32 |
| Total, serious adverse events | Atacand .05 mg | 6 | |
| Total, serious adverse events | Atacand .20 mg | 5 | |
| Total, serious adverse events | Atacand .40 mg | 4 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20160654 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00244621
GET https://conductscience.org/api/trials/v1/NCT00244621/events?page=2